MA41174B1 - Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta - Google Patents

Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Info

Publication number
MA41174B1
MA41174B1 MA41174A MA41174A MA41174B1 MA 41174 B1 MA41174 B1 MA 41174B1 MA 41174 A MA41174 A MA 41174A MA 41174 A MA41174 A MA 41174A MA 41174 B1 MA41174 B1 MA 41174B1
Authority
MA
Morocco
Prior art keywords
inhibitors
pi3kbeta
derivatives used
compounds
imidazopyridazine derivatives
Prior art date
Application number
MA41174A
Other languages
English (en)
French (fr)
Other versions
MA41174A (fr
Inventor
Laurence Mevellec
Elisabeth Pasquier
Guillaume Mercey
Lieven Meerpoel
Didier Berthelot
Sophie Coupa
Virginie Poncelet
Isabelle Pilatte
Olivier Querolle
Christophe Meyer
Patrick Angibaud
Christophe Demestre
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41174A publication Critical patent/MA41174A/fr
Publication of MA41174B1 publication Critical patent/MA41174B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Taps Or Cocks (AREA)
MA41174A 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta MA41174B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS
EP15810784.7A EP3233862B1 (en) 2014-12-19 2015-12-18 Imidazopyridazine derivatives as pi3kbeta inhibitors

Publications (2)

Publication Number Publication Date
MA41174A MA41174A (fr) 2017-10-25
MA41174B1 true MA41174B1 (fr) 2019-09-30

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41174A MA41174B1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Country Status (26)

Country Link
US (1) US10087187B2 (enExample)
EP (1) EP3233862B1 (enExample)
JP (1) JP6568588B2 (enExample)
KR (1) KR20170095239A (enExample)
CN (1) CN107108634B (enExample)
AU (1) AU2015366190B2 (enExample)
BR (1) BR112017012930A2 (enExample)
CA (1) CA2967551A1 (enExample)
CY (1) CY1122381T1 (enExample)
DK (1) DK3233862T3 (enExample)
EA (1) EA029789B1 (enExample)
ES (1) ES2761051T3 (enExample)
HR (1) HRP20191550T1 (enExample)
HU (1) HUE045220T2 (enExample)
IL (1) IL252866B (enExample)
LT (1) LT3233862T (enExample)
MA (1) MA41174B1 (enExample)
MD (1) MD3233862T2 (enExample)
ME (1) ME03517B (enExample)
MX (1) MX2017008074A (enExample)
PL (1) PL3233862T3 (enExample)
PT (1) PT3233862T (enExample)
RS (1) RS59301B1 (enExample)
SI (1) SI3233862T1 (enExample)
SM (1) SMT201900509T1 (enExample)
WO (1) WO2016097347A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6912460B2 (ja) 2015-10-09 2021-08-04 ヤンセン ファーマシューティカ エヌ．ベー． ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体
JP7149854B2 (ja) 2016-06-16 2022-10-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
CN110461827A (zh) 2017-03-29 2019-11-15 詹森药业有限公司 作为PI3K-β抑制剂的喹喔啉和吡啶并吡嗪衍生物
JP7637328B2 (ja) 2019-02-07 2025-02-28 ベイジーン リミテッド Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
JP2010502716A (ja) 2006-09-07 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターロイキン１受容体関連キナーゼの調節物質
US20100305113A1 (en) * 2007-05-09 2010-12-02 Hans-Georg Capraro Substituted Imidazopyridazines as Lipid Kinase Inhibitors
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
KR20100128305A (ko) * 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
PT2624696T (pt) 2010-10-06 2017-03-21 Glaxosmithkline Llc Derivados de benzimidazole como inibidores da cinase pi3
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8906910B2 (en) 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
HUE045220T2 (hu) 2019-12-30
KR20170095239A (ko) 2017-08-22
JP6568588B2 (ja) 2019-08-28
PL3233862T3 (pl) 2020-01-31
MA41174A (fr) 2017-10-25
MD3233862T2 (ro) 2019-11-30
BR112017012930A2 (pt) 2018-01-09
EP3233862B1 (en) 2019-07-03
CY1122381T1 (el) 2021-01-27
IL252866B (en) 2020-09-30
WO2016097347A1 (en) 2016-06-23
LT3233862T (lt) 2019-09-10
IL252866A0 (en) 2017-08-31
DK3233862T3 (da) 2019-10-07
EA029789B1 (ru) 2018-05-31
CN107108634A (zh) 2017-08-29
EA201791396A1 (ru) 2017-10-31
EP3233862A1 (en) 2017-10-25
MX2017008074A (es) 2018-01-09
PT3233862T (pt) 2019-10-09
AU2015366190A1 (en) 2017-05-25
CA2967551A1 (en) 2016-06-23
ES2761051T3 (es) 2020-05-18
ME03517B (me) 2020-04-20
SI3233862T1 (sl) 2019-09-30
CN107108634B (zh) 2020-09-15
US20180002336A1 (en) 2018-01-04
US10087187B2 (en) 2018-10-02
SMT201900509T1 (it) 2019-11-13
RS59301B1 (sr) 2019-10-31
HRP20191550T1 (hr) 2019-11-29
AU2015366190B2 (en) 2020-01-23
JP2017538734A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA33768B1 (fr) Triazolopyridines
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
AU2020231934A8 (en) Compounds useful in HIV therapy
EA202090448A1 (ru) Дигидрооксадиазиноны
MA34308B1 (fr) Triazolopyridines substituées
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine